QUOTED. 25 July 2019. Michael Mussallem.
Edwards Lifesciences is giving up on its Centera transcatheter aortic valve replacement (TAVR) despite promising clinical results and will focus on its Sapien TAVR line. See what Michael Mussallem, Edwards's CEO, said about it here.
"Although we’re really pleased and excited about Centera, and there’s a number of clinicians who are as well, and that valve performed well, the way that valve delivers didn’t work as well in all anatomies as we would have liked. So it would’ve required us to make some enhancements to the delivery system." – Michael Mussallem, CEO, Edwards Lifesciences
Click here for a free trial of Medtech Insight